493 related articles for article (PubMed ID: 25797172)
1. IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?
Ujiie H
J Dermatol Sci; 2015 Apr; 78(1):5-10. PubMed ID: 25797172
[TBL] [Abstract][Full Text] [Related]
2. Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII.
Nishie W
J Dermatol Sci; 2014 Mar; 73(3):179-86. PubMed ID: 24434029
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
4. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases.
van Beek N; Schulze FS; Zillikens D; Schmidt E
Expert Rev Clin Immunol; 2016; 12(3):267-77. PubMed ID: 26588556
[TBL] [Abstract][Full Text] [Related]
5. Exploring mechanisms of IgE-mediated autoimmunity through the lens of bullous pemphigoid.
Messingham KN; Randall G; Fairley J
G Ital Dermatol Venereol; 2016 Apr; 151(2):186-97. PubMed ID: 26959553
[TBL] [Abstract][Full Text] [Related]
6. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses.
Feliciani C; Caldarola G; Kneisel A; Podstawa E; Pfütze M; Pfützner W; Hertl M
Br J Dermatol; 2009 Aug; 161(2):306-12. PubMed ID: 19485996
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin E and bullous pemphigoid.
Cozzani E; Gasparini G; Di Zenzo G; Parodi A
Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
[TBL] [Abstract][Full Text] [Related]
8. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses.
Fania L; Caldarola G; Müller R; Brandt O; Pellicano R; Feliciani C; Hertl M
Clin Immunol; 2012 Jun; 143(3):236-45. PubMed ID: 22534318
[TBL] [Abstract][Full Text] [Related]
9. IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230).
Ghohestani RF; Cozzani E; Delaporte E; Nicolas JF; Parodi A; Claudy A
J Clin Immunol; 1998 May; 18(3):202-9. PubMed ID: 9624579
[TBL] [Abstract][Full Text] [Related]
10. Anti-collagen XVII single-chain Fv antibody blocks the autoimmune reaction mediated by pathogenic autoantibodies in bullous pemphigoid.
Wu Y; Sun NN; Dang EL; Jin L; Liu ZF; Zhang W; Yang LT; Wang G
J Dermatol Sci; 2013 Oct; 72(1):25-31. PubMed ID: 23827201
[TBL] [Abstract][Full Text] [Related]
11. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
Döpp R; Schmidt E; Chimanovitch I; Leverkus M; Bröcker EB; Zillikens D
J Am Acad Dermatol; 2000 Apr; 42(4):577-83. PubMed ID: 10727301
[TBL] [Abstract][Full Text] [Related]
12. IgE autoantibodies against the intracellular domain of BP180.
Dresow SK; Sitaru C; Recke A; Oostingh GJ; Zillikens D; Gibbs BF
Br J Dermatol; 2009 Feb; 160(2):429-32. PubMed ID: 18808416
[TBL] [Abstract][Full Text] [Related]
13. Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.
Seyed Jafari SM; Gadaldi K; Feldmeyer L; Yawalkar N; Borradori L; Schlapbach C
Front Immunol; 2019; 10():1919. PubMed ID: 31474990
[TBL] [Abstract][Full Text] [Related]
14. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid.
Dimson OG; Giudice GJ; Fu CL; Van den Bergh F; Warren SJ; Janson MM; Fairley JA
J Invest Dermatol; 2003 May; 120(5):784-8. PubMed ID: 12713582
[TBL] [Abstract][Full Text] [Related]
15. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
16. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid.
Hashimoto T; Ohzono A; Teye K; Numata S; Hiroyasu S; Tsuruta D; Hachiya T; Kuroda K; Hashiguchi M; Kawakami T; Ishii N
Br J Dermatol; 2017 Jul; 177(1):141-151. PubMed ID: 27716903
[TBL] [Abstract][Full Text] [Related]
17. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
[TBL] [Abstract][Full Text] [Related]
18. IgG antibodies against immunodominant C-terminal epitopes of BP230 do not induce skin blistering in mice.
Feldrihan V; Licarete E; Florea F; Cristea V; Popescu O; Sitaru C; Chiriac MT
Hum Immunol; 2014 Apr; 75(4):354-63. PubMed ID: 24468586
[TBL] [Abstract][Full Text] [Related]
19. Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin.
Ishiko A; Shimizu H; Kikuchi A; Ebihara T; Hashimoto T; Nishikawa T
J Clin Invest; 1993 Apr; 91(4):1608-15. PubMed ID: 7682575
[TBL] [Abstract][Full Text] [Related]
20. IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid.
Delaporte E; Dubost-Brama A; Ghohestani R; Nicolas JF; Neyrinck JL; Bergoend H; Janin A; Capron M
J Immunol; 1996 Oct; 157(8):3642-7. PubMed ID: 8871665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
